Successor’s Celebrex® Patent Dispute — With BYU — Settles

I note — simply to complete the Celebrex® record, here — that Pfizer, as the successor to Pharmacia last led by Fred Hassan and Carrie Cox (the last pharma before Schering-Plough!), has settled a multi-year series of patent disputes in Utah federal District Court overnight — on confidential terms.

It is known that Pfizer will create an endowed chair for Dr. Daniel Simmons, an alleged largely uncredited co-inventor of the COX-2 inhibitor compounds — one of which became Celebrex.

I should also note that the Hassan/Cox launch and marketing efforts on Celebrex, including allegedly delaying unfavorable study results — led to what remains the largest criminal fine in multinational pharma history. Fabulous.

Here’s a 12-page PDF of the last responsive pleading in the Utah patent dispute. [When one is reduced to arguing that press releases are confidential documents. . . one is likely on the losing end of an argument. Heh.]

From the Pfizer press release, then:

. . . .The parties to Brigham Young University and Dr. Daniel Simmons v. Pfizer Inc. et al., a matter in the United States Court for the District of Utah, Central Division, announce that they have reached an amicable settlement on confidential terms. As part of the resolution, BYU will establish the Dan Simmons Chair in recognition of Dr. Simmons’ lifelong work and contributions towards advancing human health in a number of important areas including oncology, pain and Alzheimer’s.

We are pleased to resolve this matter and the uncertainty of litigation and to be in a position to support Dr. Simmons’ research efforts at BYU. . . .

Not with a bang — but with a whimper — it ends.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s